Format

Send to

Choose Destination
See comment in PubMed Commons below
Arch Neurol. 2005 Nov;62(11):1734-6.

Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia.

Author information

1
Molecular Medicine Laboratory, University of Pavia, IRCCS San Matteo Hospital, Pavia, Italy.

Abstract

BACKGROUND:

The receptor for advanced glycation end products (RAGE) is a cell surface receptor that has been implicated in vascular disease and neurodegeneration. Low levels of its secreted isoform, soluble RAGE (sRAGE), have been regarded as a putative risk factor for atherosclerosis. In addition, administration of sRAGE has been shown to reduce development of cerebral beta-amyloidosis in an Alzheimer disease mouse model.

OBJECTIVE:

To investigate the role of sRAGE as a biological marker for Alzheimer disease and vascular dementia.

DESIGN:

Cross-sectional study of 152 patients with a clinical diagnosis of Alzheimer disease, 91 with vascular dementia and 161 control subjects.

MAIN OUTCOME MEASURE:

Plasma levels of sRAGE.

RESULTS:

Levels of sRAGE were significantly reduced in the plasma of patients with Alzheimer disease compared with that for those with either vascular dementia (P<.05) or with controls (P<.001).

CONCLUSIONS:

Patients with Alzheimer disease have reduced levels of sRAGE in plasma compared with patients with vascular dementia and controls. The striking reduction of circulating sRAGE in Alzheimer disease further supports a role for the RAGE axis in this clinical entity and requires further investigation.

PMID:
16286548
DOI:
10.1001/archneur.62.11.1734
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Silverchair Information Systems
    Loading ...
    Support Center